Axa S.A. Maxcyte, Inc. Transaction History
Axa S.A.
- $32.2 Billion
- Q4 2024
A detailed history of Axa S.A. transactions in Maxcyte, Inc. stock. As of the latest transaction made, Axa S.A. holds 986,897 shares of MXCT stock, worth $3.97 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
986,897Holding current value
$3.97 Million% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding MXCT
# of Institutions
123Shares Held
69.8MCall Options Held
8.7KPut Options Held
6K-
Cadian Capital Management, LP New York, NY9.34MShares$37.6 Million2.26% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$32.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.43MShares$21.8 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$20.3 Million18.06% of portfolio
-
Morgan Stanley New York, NY4.41MShares$17.7 Million0.0% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $409M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...